"Moderna's Push for Accelerated Approval of Cancer Vaccine Hinges on Three Key Factors"

Moderna is aiming for an accelerated approval for its cancer vaccine in partnership with Merck by 2025, following promising Phase II data showing the potential of their individualized neoantigen therapy in reducing the risk of cancer recurrence or death in melanoma patients when used with Merck’s Keytruda. However, the company is waiting on three key developments before seeking accelerated approval. The therapy is currently undergoing Phase III trials in adjuvant melanoma and non-small cell lung cancer.